NCT01186484View on ClinicalTrials.gov

Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 1, 2010

Primary Completion Date

October 2, 2014

Study Completion Date

October 2, 2014

Conditions
Prostatic Neoplasms
Interventions
DRUG

JNJ-212082

250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.

Trial Locations (5)

Unknown

Fukuoka

Kashiwa

Kōtoku

Sunto

Yokohama

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY